HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.

AbstractBACKGROUND:
Due to the absence of specific symptoms and low survival rate, efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis are urgently required. The purpose of this study was to evaluate the diagnostic performance of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and to determine the optimal cutoff values for HBV infection-related HCC.
METHODS:
We conducted a cross-sectional, multi-center study in China to ascertain the cutoff value for HCC patients in the context of CHB- and HBV-related cirrhosis. The receiver operating characteristic curve (ROC) and the area under the curve (AUC) were used to evaluate the diagnostic performance of PIVKA-II.
RESULTS:
This study enrolled 784 subjects and demonstrated that PIVKA-II had a sensitivity of 84.08% and a specificity of 90.43% in diagnosis HCC from chronic liver diseases. PIVKA-II at a cutoff of 37.5 mAU/mL yielded an AUC of 0.9737 (sensitivity 91.78% and specificity 96.30%) in discriminating HCC from chronic hepatitis B (CHB) patients. PIVKA-II at a cutoff of 45 mAU/mL yielded an AUC of 0.9419 (sensitivity 77.46% and specificity 95.12%) in discriminating HCC- from HBV-related cirrhosis patients. Furthermore, using a cutoff value of 40 mAU/mL for PIVKA-II as an HCC marker, only 4.81% (15/312) was positive in chronic hepatitis and 12.80% (37/289) in cirrhosis patients, revealing the satisfactory specificity of PIVKA-II in chronic liver disease of different etiologies.
CONCLUSION:
Our data indicated that PIVKA-II had satisfactory diagnostic efficiencies and could be used as a screening or surveillance biomarker in HCC high-risk population.
AuthorsJun Ji, Lijuan Liu, Feifei Jiang, Xue Wen, Yu Zhang, Shengcong Li, Jinli Lou, Ying Wang, Ning Liu, Qiuyan Guo, Yongmei Jia, Chunfang Gao
JournalJournal of clinical laboratory analysis (J Clin Lab Anal) Vol. 35 Issue 11 Pg. e24013 (Nov 2021) ISSN: 1098-2825 [Electronic] United States
PMID34590755 (Publication Type: Journal Article, Multicenter Study)
Copyright© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Chemical References
  • Biomarkers
  • Protein Precursors
  • acarboxyprothrombin
  • Prothrombin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers (blood)
  • Carcinoma, Hepatocellular (blood, diagnosis)
  • Cross-Sectional Studies
  • Female
  • Humans
  • Immunoassay
  • Liver Diseases (blood, diagnosis)
  • Liver Neoplasms (blood, diagnosis)
  • Male
  • Middle Aged
  • Protein Precursors (blood)
  • Prothrombin
  • Sensitivity and Specificity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: